Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

Corporate Breaking News

Home : Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

Sep 30 2019	Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019
NORTH BRUNSWICK, New Jersey, Sept. 30, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and effective drugs with a focus on Oncology, announced today...


Source:https://www.prnewswire.com:443/news-releases/adlai-nortye-presents-encouraging-phase-1b-study-data-of-an0025-an-oral-ep4-antagonist-for-locally-advanced-rectal-cancer-at-esmo-2019-300927464.html

Related News
» Tetragon Financial Group Limited August 2019 Monthly Factsheet » The 10th China (Taizhou) International Medical Expo successfully ended